Exchange: NASDAQ·Updated 06:52 PM EDT
CVKD logo

CVKDCadrenal Therapeutics, Inc.

$2.04
$0.01
(0.49%)
Today
Closed $2.04
$0.0726
(3.56%)
After Hours
Mkt Cap$6.32M
Vol80,260.00
News
all
press releases
CVKD Stock Retail Sentiment Peaks After FDA Clears Phase 3 Path For Blood Clot Drug
Its late-stage trial targets 120 patients globally, with results aimed at pushing for a potential NDA filing in 2029.
Stocktwits
More News
Why Is Cadrenal Therapeutics Stock Drawing Retail Attention Today?
The company said VLX-1005 targets a high-risk heparin complication with limited treatment options.
Stocktwits
Matthew Szot Sells 9,933 Shares of Cadrenal Therapeutics (NASDAQ:CVKD) Stock
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD - Get Free Report) CFO Matthew Szot sold 9,933 shares of the company's stock in a transaction dated Monday, December 29th. The shares were sold at an average...
MarketBeat
Why the underdog mindset could be your business superpower
You can catch Warrior Money on Apple Podcasts, Spotify, Amazon Music, or wherever you get your podcasts. What does it take to go from refugee kid to Marine pilot, biotech CEO, and author? On this...
Yahoo! Finance-YouTube
Cadrenal Therapeutics, Inc.
CVKD: Acquires Factor XIa Inhibitors
Zacks
Cadrenal Therapeutics Expands Pipeline With Portfolio Acquisition Worth Up To $15 Million
The company said that the acquisition will significantly enhance its pipeline by adding novel assets in acute and chronic anticoagulation settings.
Stocktwits
<
...
1
>

Advertisement|Remove ads.